Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 2 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Eisai has taken an aggressive approach in seeking out the right partners to fill out its pipelines. The company's partnership with Swedish startup BioArctic to develop a drug for Alzheimer's disease is no exception. Eisai and BioArctic discussed the beginnings of their partnership in the first part of this case study (PharmAsia News, Aug. 6, 2008). This second section discusses in greater detail why the companies view the partnership as a success and what each has brought to the other.
Advertisement

Related Content

Eisai’s Ontak sBLA Granted U.S. FDA Approval
Eisai’s Ontak sBLA Granted U.S. FDA Approval
Bayer Signs Licensing Agreement With Nagasaki University For Alzheimer’s Diagnosis Compounds
Bayer Signs Licensing Agreement With Nagasaki University For Alzheimer’s Diagnosis Compounds
Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)
Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
Rethinking Alzheimer's: Mapping Out an Approval Process
Advertisement
UsernamePublicRestriction

Register

SC069234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel